Cancer Biologics Market Size to Touch USD 214.59 Bn by 2033

Key Points

• North America dominated the cancer biologics market in 2023
• Asia Pacific is expected to grow steadily in the market during the forecast period.
• The monoclonal antibodies segment dominated the market by drug class in 2023.
• The cancer growth inhibitors segment is expected to grow to the highest CAGR in the market by application during the forecast period.
• The blood cancer segment dominated the market by application in 2023.
• The lung cancer segment is expected to grow to the highest CAGR in the market by application during the forecast period.
• In 2023, the hospital segment dominated the market by end-use.
• The cancer center segment is expected to grow to the highest CAGR in the market by end-use during the forecast period.

The cancer biologics market has witnessed substantial growth in recent years, driven by advancements in biotechnology and increasing investment in research and development. Biologics, which are derived from living organisms, offer targeted therapies with fewer side effects compared to traditional treatments like chemotherapy. This has led to a significant shift towards biologics in cancer treatment, fueling the expansion of the market globally.

Get a Sample: https://www.precedenceresearch.com/sample/4005

Growth factors driving the cancer biologics market include the rising incidence of cancer worldwide, particularly in developing regions. Additionally, the growing understanding of cancer biology and the development of personalized medicine have spurred demand for biologics tailored to individual patient profiles. Moreover, favorable government initiatives and increasing healthcare expenditure have facilitated market growth by enhancing accessibility to advanced cancer treatments.

Cancer Biologics Market Scope

Cancer Biologics Market Dynamics

Regionally, North America dominates the cancer biologics market, attributed to the presence of key biotechnology and pharmaceutical companies, well-established healthcare infrastructure, and high adoption rates of innovative therapies. Europe follows closely, driven by robust research activities, supportive regulatory frameworks, and increasing collaborations between academia and industry players. Furthermore, the Asia-Pacific region is experiencing rapid growth due to improving healthcare infrastructure, rising disposable incomes, and a growing patient pool.

Key drivers propelling the cancer biologics market forward include ongoing advancements in biotechnology, such as the development of monoclonal antibodies, immunotherapies, and targeted therapies. These innovative treatment modalities offer superior efficacy and reduced toxicity compared to conventional treatments, thereby driving their adoption in cancer management. Additionally, strategic collaborations and partnerships between pharmaceutical companies and research institutions are accelerating the development and commercialization of novel biologics.

Amidst the growth opportunities, the cancer biologics market faces several challenges. High development costs, stringent regulatory requirements, and lengthy approval processes pose barriers to market entry for small and medium-sized enterprises. Moreover, manufacturing complexities associated with biologics production and the need for stringent quality control measures add to the operational challenges faced by industry players. Furthermore, patent expirations and the emergence of biosimilars pose threats to market incumbents, leading to increased competition and pricing pressures.

Read Also: Urinalysis Market Size to Cross USD 3.65 Billion by 2033

Recent Developments

• Dr. Reddy’s Laboratories declared in March 2024 that Versavo® (bevacizumab) would be available in the UK. Avastin’s biosimilar Versavo is effective against multiple cancer types, such as advanced non-squamous non-small cell lung cancer, metastatic colorectal cancer, ovarian cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and metastatic breast cancer.
• BioNTech and Duality Biologics declared in January 2024 that a Phase III trial of a medication for breast cancer has begun. BioNTech and Duality are conducting a Phase III trial to evaluate their antibody-drug conjugate in patients whose tumors have low levels of progesterone or estrogen and respond to these hormones. This corresponds to between 40% and 45% of patients with metastatic breast cancer who are on Herceptin for HER2.
• Angle, a liquid biopsy firm that provides diagnostic solutions for circulating tumor cells (CTCs) in drug development, research, and clinical oncology, announced in November 2023 that the Portrait PD-L1 test would be available for CTCs to assess PD-L1 protein expression.
• In April 2023, TORL BioTherapeutics LLC, a biopharmaceutical company focused on developing new biologics for cancer treatment, announced its public launch and the closing of a $158 million Series B financing.

Cancer Biologics Market Companies

• Abbott
• Angel
• Amgen, Inc
• AstraZeneca
• BioNTech
• Bristol-Mayer Squibb Company
• Dr. Reddy’s Laboratories
• Duality Biologics
• Eli Lilly and Company
• F.Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• Glenmark Pharmaceuticals Ltd
• GSK plc.
• Ichnos Sciences Inc
• Johnson & Johnson Services, Inc
• Pfizer, Inc
• TFC Therapeutics

Segments Covered in the Report

By Drug Class

• Monoclonal Antibodies
  • Naked Monoclonal Antibodies
  • Conjugated Monoclonal Antibodies
  • Bispecific Monoclonal Antibodies
• Cancer Growth Inhibitors
  • Tyrosine Kinase Inhibitor
  • Mtor Inhibitors
  • Proteasome Inhibitors
  • Others
• Vaccines
  • Preventive Vaccines
  • Therapeutic Vaccines
• Recombinants Proteins
• CAR-T Cells
• Angiogenesis Inhibitors
• Interleukins (IL)
• Interferons (IFN)
• Gene Therapy
• Others

By Applications

• Blood Cancer
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Gastric Cancer
• Ovarian Cancer
• Skin Cancer
• Liver Cancer
• Others

By End use

• Hospitals
• Cancer Center
• Academics & Research Institutes

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/